Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease

Acta Neurologica Scandinavica

Volumn 114, Issue 2, 2006, Pages 97-101

  Mauri, M ^a,b   Mancioli, A ^a   Rebecchi, V ^a   Corbetta, S ^a   Colombo, C ^a   Bono, G ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Agitation; Alzheimer's disease; Amisulpride; Disruptive behaviour

Indexed keywords

AMISULPRIDE; DONEPEZIL; RIVASTIGMINE;

AGED; AGITATION; ALERTNESS; ALZHEIMER DISEASE; APPETITE DISORDER; ARTICLE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTOR ACTIVITY; NEUROPSYCHIATRY; OUTPATIENT; PARKINSON DISEASE; RATING SCALE; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; AGGRESSION; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; AROUSAL; COGNITION; FEMALE; HUMANS; IRRITABLE MOOD; MALE; MENTAL DISORDERS; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA, PARANOID; SULPIRIDE; TREATMENT OUTCOME;

EID: 33745825594     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00660.x     Document Type: Article

References (28)

1. ASSAL F, CUMMINGS JL. Neuropsychiatric symptoms in dementias. Curr Opin Neurol 2002;15:445-50.
2. BULLOCK R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 2005;21:1-10.
3. FINKEL SI. Effect of rivastigmine on behavioural and psychological symptoms of dementia in Alzheimer's disease. Clin Ther 2004;26:980-90.
4. CUMMINO JL, SCHNEIDER L, TARIOT PN, KERSHAW PR, YUAN W. Reduction of behavioural disturbance and caregiver distresfs by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532-8.
5. HOLMES C, WILKINSON D, VETHANAYAOAM S et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer's disease. Neurology 2004;63:214-19.
6. CURRAN MP, PERRY CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001;61:2123-50.
7. COULOUVRAT C, DONDEY-NOUVEL L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1998;14:209-18.
8. AOELINK MW, MAJEWSKI T, WURTHMANN C, LUKAS K, ULRICH H, LIMKA T, KLIESER E. Effects of newer antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole and clozapine. J Clin Psychopharmacol 2001;21:8-13.
9. TAYLOR D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003;17:423-30.
10. VIEWEG WV, SCNEIDER RK, WOOD MA. pointes in patients with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 2005;12:318-22.
11. DE DEYN P, JESTE DV, SWANINK R et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomised, placebo-controlled study. J Clin Psychopharmacol 2005;25:463-7.
12. MCKHANN G, DRACHMAN D, FOLSTEIN M, KATZMAN R, PRICE D, STADLAN EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
13. CUMMINGS JL, MEGA M, GRAY K, ROSENBERGER-THOMPSON S, CARUSI DA, GORNBEIN J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
14. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR Mini mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-98.
15. HUGHES CP, BERG L, DANZIGER WL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72.
16. KATZ S. The index of AD: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-9.
17. FAHN S, ELTON RL, the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease, vol. 2. Floram Park, NJ, McMillan Health Care Information, 1987; 153-64.
18. DANIEL DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000;61:49-52.
19. STEELE C, ROVNER B, CHASE A. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-51.
20. IKEDA M, FUKUHARA R, SHIGENOBU K et al. Dementia associated mental and behavioural disturbances in elderly people in the community: findings from the first Nakayama study. J Neurol, Neurosurg Psychiatry 2004;75:146-8.
21. LYSKETOS CG, STEINBERG M, TSCHANZ JT et al. Mental and behavioral distubances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry 2000;157:708-14.
22. FIROZ A. Dementia: targeting noncognitive symptoms. Can J CME 2005;5:83-6.
23. BOYER P, LECRUBIER AJ, PEUCH J et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72.
24. COLONNA L, SALEEM P, DONDEY-NOUVEL L, REIN W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22.
25. PEUSKENS J, BECK P, MOLLER HJ, BALE R, FLEUROT O, REIN W. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study Group. Psychiatry Res 1999;88:107-17.
26. WETZEL H, GRUNDER G, HILLERT A. Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology - a double blind controlled study comparing a selective D2-like antagonist to a mixed D1/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology 1998;137:223-32.
27. SENANARONG V, CUMMINGS JL, FAIRBANKS L et al. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord 2004;17:14-20.
28. CALTAGIRONE C, BIANCHETTI A, DE LUCA M et al. Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drug Aging 2005;22:1-40.